Atopic Dermatitis

Experts in dermatology comment on how often quickness of response to therapy determines treatment selection for teenaged patients with AD.

Expert dermatologists discuss treatment selection for short-term rescue vs long-term maintenance therapy.

Del Rosso previews his upcoming sessions at SCALE 2023 discussing the latest updates in management and treatment techniques.

New data from Dermavant showed high levels of efficacy and statistical significance for the topical cream, which is expected to have an sNDA on file with the US FDA in early 2024.

Researchers linked proximity to heavy traffic roadways and risk of atopic dermatitis.

Patients with atopic dermatitis were asked to rate the importance of several factors that may influence their decision to participate in a clinical trial.

Andrew Blauvelt, MD, MBA, reviews systemic vs topical treatment of AD, discussion patient preferences as a factor for treatment selection.

Experts in dermatology discuss the rapidly expanding treatment landscape of atopic dermatitis and how these new treatment options have changed the management of AD.

Adam Friedman, MD, FAAD, discusses his RAD 2023 session, "Using Teledermatology to Reduce Disparities in Atopic Dermatitis."

Experts in the field share why they enjoyed the 5th Annual Revolutionizing Atopic Dermatitis Conference and why it is unique.

Catch up on all coverage from Revolutionizing Atopic Dermatitis.

A single-site study involving an adult cohort with atopic dermatitis saw significant itch improvement.

Alexis discusses his Revolutionizing Atopic Dermatitis session, “Disparities in the Care of Atopic Dermatitis in the United States.”

New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.

The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.

The drug was both safe and effective in patients ages 6 months to 5 years.

Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.

Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.

Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.

Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.